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FPIN's Clinical Inquiries 
Treatment of Herpes Zoster 
Clinical Question 
What is the best treatment for patients with an outbreak of herpes zoster? 
Evidence-Based Answer 
Resolution of acute pain related to herpes zoster is accelerated with any of the following: oral 
acyclovir (Zovirax) 800 mg five times daily for seven days; valacyclovir (Valtrex) 1,000 mg 
three times daily for seven days; or famciclovir (Famvir) 750 mg once daily, 500 mg twice daily, 
or 250 mg three times daily for seven days. (Strength of recommendation: A) 
Famciclovir and acyclovir are similarly effective at improving the rate of lesion healing. 
(Strength of recommendation: B) 
Oral valacyclovir may be slightly superior to acyclovir for resolution of acute pain. (Strength of 
recommendation: B) 
Acyclovir 800 mg five times daily for seven to 10 days reduces the occurrence of postherpetic 
neuralgia. (Strength of recommendation: A) 
Oral corticosteroids given during the acute phase of the illness have not been shown to reduce 
the incidence or severity of postherpetic neuralgia. (Strength of recommendation: B) 
There is no evidence to support the use of tricyclic antidepressants or anticonvulsants for the 
management of herpes zoster. (Strength of recommendation: B) 
Evidence Summary 
Table 11-5 is a summary of the outcomes of five studies of treatment of herpes zoster patients. 
Table 1 
Summary of Treatment Outcomes for Herpes Zoster: Systematic Reviews and 
Randomized Control Trials (RCTs) 
Study Outcome 
Wood, et al1 
(n=1076), meta-
analysis 
Acyclovir (Zovirax) 800 mg five times daily for seven days is better 
than placebo for resolution of pain 
Beutner, et al2 
(n=760), RCT 
Valacyclovir (Valtrex) 1,000 mg three times daily for seven days is 
better than acyclovir 800 mg five times daily for seven days for 
resolution of pain. 
Tyring, et al3 
(n=419), RCT 
Famciclovir (Famvir) 500 mg three times daily or 750 mg three 
times daily for seven days increases rate of lesion healing better than 
placebo. 
Shen, et al4 
(n=55), RCT 
Famciclovir 250 mg three times daily for seven days is equal to 
acyclovir 800 mg five times daily for seven days for resolution of 
pain and rate of lesion healing. 
Shafran, et al5 
(n=559), RCT  
Famciclovir 750 mg once daily for seven days, 500 mg twice daily 
for seven days, 250 mg three times daily for seven days, and 
acyclovir 800 mg five times daily for seven days are all equally 
effective for resolution of pain and rate of lesion healing. 
 
Information from references 1 through 5. 
treatment of acute herpes zoster 
A meta-analysis of five randomized controlled trials (RCTs) considered the time to complete 
resolution of acute herpes zoster pain.1 When treatment (acyclovir 800 mg five times daily for 
seven days) was initiated within 48 hours, complete resolution of pain occurred sooner than with 
placebo (28 versus 62 days, P < .005). This also was true when treatment was initiated between 
48 and 72 hours (28 versus 58 days, P = .04). 
A single RCT2 compared valacyclovir (1,000 mg three times daily for seven days) with 
acyclovir (800 mg five times daily for seven days). This study found that the mean times to 
complete resolution of pain were 44 days for valacyclovir and 51 days for acyclovir when treated 
within 48 hours (P = .03).2 When treatment was initiated between 48 and 72 hours after the onset 
of symptoms, the mean times to complete resolution of pain were 36 days for valacyclovir and 
48 days for acyclovir (P = .02). 
Another RCT3 compared two dosage regimens of famciclovir (500 mg three times daily for 
seven days or 750 mg three times daily for seven days) with placebo in 419 adults treated within 
72 hours of symptom onset. Famciclovir slightly accelerated the rate of lesion healing compared 
with placebo (median difference of one to two days for different doses and lesion endpoints). 
In a single RCT4 with 55 patients, famciclovir (250 mg three times daily for seven days) was 
shown to have equal effectiveness to acyclovir (800 mg five times daily for seven days). This 
small and possibly underpowered study found that there was no significant difference regarding 
the median time to full lesion crusting, the rate of full crusting at day 28, the median time to 
resolution of acute pain, or the rate of acute pain at 28 days. 
Three different dosage regimens of famciclovir (750 mg once daily for seven days, 500 mg twice 
daily for seven days, or 250 mg three times daily for seven days) and one regimen for acyclovir 
(800 mg five times daily for seven days) were compared in another RCT5 with 559 patients 
presenting within 72 hours of onset. The time to full crusting was similar (seven to eight days) 
for all four dosage regimens. There was no significant difference in time to acute pain resolution: 
14 days for the acyclovir regimen, 17 days for famciclovir 250 mg three times daily, and 19 days 
for famciclovir 500 mg twice daily and 750 mg once daily). 
Prevention and treatment of postherpetic neuralgia 
A systematic review6 considered 42 RCTs of therapies to prevent or reduce the incidence of 
postherpetic neuralgia pain. Acyclovir (800 mg five times daily for seven to 10 days) reduced the 
incidence of postherpetic neuralgia pain at three months (number needed to treat [NNT] = 3.2 to 
8.0). 
Famciclovir reduced the duration of postherpetic neuralgia pain better than placebo.3 The time to 
resolution of pain in patients 50 years of age or older was significantly shorter for two dosages of 
famciclovir (500 mg [P = .004] or 750 mg [P = .003] given three times daily for seven days) than 
for placebo (63 versus 163 days). 
Systemic steroids have demonstrated no additional benefit. Studies examining amitriptyline, 
narcotics, capsaicin, anticonvulsants, and percutaneous nerve stimulation for postherpetic 
neuralgia were of fair to poor quality and no conclusions could be drawn from these. 
Recommendations from Others 
A consensus guideline from the International Herpes Management Forum6 recommends antiviral 
therapy with valacyclovir (1,000 mg three times daily for seven days) or famciclovir (250 mg or 
500 mg three times daily for seven days) for immunocompetent adults older than 50 years; 
treatment should be initiated within 72 hours of rash onset. Systemic oral steroids are 
recommended to reduce acute symptoms. It also is recommended that tricyclic antidepressants be 
considered to reduce the incidence of postherpetic neuralgia in older patients. Topical antiviral 
agents are not recommended. 
Clinical Commentary 
Appropriate care for patients with herpes zoster requires the entire office staff to understand the 
natural course of the illness and the need for early treatment (within 72 hours). Office assistants 
must recognize that prodromal pain symptoms or onset of rash are indications for an appointment 
that day to confirm the diagnosis and to begin treatment. Because the rash results in physical 
appearance changes, many patients have a high anxiety level about their illness. In addition, 
many myths exist about herpes zoster. Patient education should focus on infectivity, symptoms 
that require a follow-up office visit, and the importance of completing the entire course of 
medications. 
Keith b. holten, M.D. 
Denise H. Britigan, M.A.  
Clinton Memorial Hospital/University of Cincinnati 
Family Medicine Residency, Wilmington, Ohio 
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